Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home

J Nutr Health Aging. 2015 May;19(5):563-9. doi: 10.1007/s12603-015-0498-8.


Objective: To evaluate whether fortification of yogurts with vitamin D and calcium exerts an additional lowering effect on serum parathyroid hormone (PTH) and bone resorption markers (BRM) as compared to iso-caloric and iso-protein dairy products in aged white women at risk of fragility fractures.

Design: A randomized double-blind controlled trial.

Setting: A community dwelling home.

Participants: Forty-eight women over 60 years (mean age 73.4).

Intervention: Consumption during 84 days of two 125 g servings of either vitamin D and calcium-fortified yogurts (FY) at supplemental levels of 10 µg vitamin D3/d and 520 mg/d of calcium (total=800 mg/d), or non fortified control yogurts (CY) providing 280 mg/d of calcium.

Measurements: Serum changes from baseline (D0) to D28, D56 and D84 in 25OHD, PTH and in two BRM: Tartrate-resistant-acid-phosphatase-isoform-5b (TRAP5b) and carboxy-terminal-cross-linked-telopeptide of type-I-collagen (CTX).

Results: The 10 years risk of major and hip fractures were 13.1 and 5.0%, and 12.9 and 4.2 %, in FY and CY groups, respectively. From D0 to D84, serum 25OHD increased (mean±SE) from 34.3±2.4 to 56.3±2.4 nmol/L in FY (n=24) and from 35.0±2.5 to 41.3±3.0 nmol/L in CY (n=24), (P=0.00001). The corresponding changes in PTH were from 64.1±5.1 to 47.4±3.8 ng/L in FY and from 63.5±4.6 to 60.7±4.2 ng/L in CY (P=0.0011). After D84, TRAP5b was reduced significantly (P=0.0228) and CTX fell though not significantly (P=0.0773) in FY compared to CY.

Conclusion: This trial in aged white women living in a community dwelling home at risk for osteoporotic fractures confirms that fortification of dairy products with vitamin D3 and calcium should provide a greater prevention of secondary hyperparathyroidism and accelerated bone resorption as compared to non-fortified equivalent foods.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acid Phosphatase / blood
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Bone Resorption / blood*
  • Bone Resorption / diet therapy
  • Bone Resorption / prevention & control
  • Calcium, Dietary / administration & dosage*
  • Calcium, Dietary / pharmacology
  • Calcium, Dietary / therapeutic use
  • Cholecalciferol / administration & dosage*
  • Cholecalciferol / blood
  • Cholecalciferol / pharmacology
  • Cholecalciferol / therapeutic use
  • Collagen Type I / blood
  • Double-Blind Method
  • Female
  • Food, Fortified*
  • Hip Fractures / prevention & control
  • Humans
  • Hyperparathyroidism, Secondary / diet therapy
  • Hyperparathyroidism, Secondary / prevention & control
  • Isoenzymes / blood
  • Middle Aged
  • Nursing Homes*
  • Osteoporotic Fractures / prevention & control
  • Parathyroid Hormone / blood*
  • Risk
  • Tartrate-Resistant Acid Phosphatase
  • White People
  • Yogurt*


  • Biomarkers
  • Calcium, Dietary
  • Collagen Type I
  • Isoenzymes
  • Parathyroid Hormone
  • Cholecalciferol
  • Acid Phosphatase
  • Tartrate-Resistant Acid Phosphatase